Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Mirtazapine
Mawdsley-Brooks & Company Ltd
N06AX11
Mirtazapine
45mg
Orodispersible tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04030400
1.3.1 SPC, LABELLING AND PACKAGE LEAFLET PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 1. NAME OF THE MEDICINAL PRODUCT Mirtazapine 15 mg orodispersible tablets Mirtazapine Mirtazapine 30 mg orodispersible tablets Mirtazapine Mirtazapine 45 mg orodispersible tablets Mirtazapine 2. STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 15 mg mirtazapine. Each orodispersible tablet contains 30 mg mirtazapine. Each orodispersible tablet contains 45 mg mirtazapine. 3. LIST OF EXCIPIENTS Contains aspartame (E951), see leaflet for further information. 4. PHARMACEUTICAL FORM AND CONTENTS Orodispersible tablet _6 orodispersible tablets _ _18 orodispersible tablets _ _30 orodispersible tablets _ _48 orodispersible tablets _ _90 orodispersible tablets _ _96 orodispersible tablets _ 5. METHOD AND ROUTE(S) OF ADMINISTRATION _ _ Oral use. Read the package leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 1.3.1 SPC, LABELLING AND PACKAGE LEAFLET 7. OTHER SPECIAL WARNING(S), IF NECESSARY ------- 8. EXPIRY DATE EXP _ _ 9. SPECIAL STORAGE CONDITIONS ------- 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE ------- 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Bluefish Pharmceuticals AB, Stockholm, Sweden. 12. MARKETING AUTHORISATION NUMBER(S) Mirtazapine 15 mg Orodispersible Tablets: PL 31774/0013 Mirtazapine 30 mg Orodispersible Tablets: PL 31774/0014 Mirtazapine 45 mg Orodispersible Tablets: PL 31774/0015 13. BATCH NUMBER Lot 14. GENERAL CLASSIFICATION FOR SUPPLY 15. INSTRUCTIONS ON USE ------- 16. INFORMATION IN BRAILLE Mirtazapine 15 mg Mirtazapine 30 mg Mirtazapine 45 mg POM 1.3.1 SPC, LABELLING AND PACKAGE LEAFLET 17. UNIQUE IDENTIFIER – 2D BARCODE_ _ <2D barcode carrying the unique identifier included.> 18. UNIQUE IDENTIFIER - HUMAN READABLE DATA_ _ PC: {number} SN: {number} NN: {number} 1 Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mirtazapine 45 mg orodispersible tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 30 mg of mirtazapine. Excipient with known effects: 18 mg of Aspartame (E951) For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Orodispersible tablet The tablets are white or almost white, 12 mm round, biconvex, uncoated tablets and marked M4. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of depressive illness. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The tablet should be taken out of the blister with dry hands and should be placed on the tongue. The tablet will disintegrate and can be swallowed without water. The tablet should be swallowed without chewing. Adults: Treatment should begin with 15 mg daily. The dosage generally needs to be increased to obtain an optimal clinical response. The effective daily dose is usually between 15 and 45 mg. Elderly: The recommended dose is the same as that for adults. In elderly patients an increase in dosing should be done under close supervision to elicit a satisfactory and safe response. Children: Since safety and efficacy of Mirtazapine has not been established in children, it is not recommended to treat children with Mirtazapine. Two randomised placebo-controlled trials failed to demonstrate efficacy for Mirtazapine in the treatment of children and adolescents with major depressive disorder. Safety and efficacy of Mirtazapine in paediatric depression can not be extrapolated from adult data. Children and adolescents under the age of 18 years Mirtazapine Tablets should not be used in children and adolescents under the age of 18 years as efficacy was not demonstrated in two short-term clinical trials (see section 5.1) and because of safety concerns (see sections 4.4, 4.8 and 5.1). The clearance of mirtazapine may be decreased in patients with renal or hepatic insufficiency. This should be taken into account when prescribing Mirtazapine to this category of patients. Mirt Read the complete document